News Outlet:

Reuters

 

CFD Research Corporation has been awarded a $1.3 million grant from the National Institutes of Health to develop their novel in vitro tumor model. SynVivo-Tumor replicates the tumor microenvironment with physiologically and morphologically realistic microvasculature including endothelial cell-lined leaky vessels and 3D solid tumors. Tumor drug delivery is a complex phenomenon affected by several elements in addition to physico-chemical properties. 
 
"Current in vitro models of tumor drug delivery are oversimplified and show poor correlation with in vivo performance," said Prabhakar Pandian, Ph.D., CFDRC principal investigator. "Our novel platform mimics the in vivo environment with physiologically relevant flow resulting in endothelial cell lined capillary vessels and 3D solid tumors. Most importantly, the SynVivo-Tumor platform enables real-time, quantitative assessment of the performance of drug delivery vehicles."
The entire article from Reuters can be read here
 
About CFDRC
CFD Research Corporation develops and commercializes innovative technologies for biomedical, energy, and aerospace markets. CFDRC, founded in 1987, is headquartered in Huntsville, Ala. The  biomedical division is located with the Huntsville-based HudsonAlpha Institute for Biotechnology.
 
Contact: Richard Thoms
Manager, Technology Partnerships
rdt@cfdrc.com
256-726-4810